Venetoclax in chronic lymphocytic leukaemia: a possible cure?
- 1 September 2018
- journal article
- editorial
- Published by Elsevier in The Lancet Oncology
- Vol. 19 (9) , 1143-1144
Abstract
No abstract availableThis publication has 7 references indexed in Scilit:
- Bendamustine followed by obinutuzumab and venetoclax in chronic lymphocytic leukaemia (CLL2-BAG): primary endpoint analysis of a multicentre, open-label, phase 2 trialThe Lancet Oncology, 2018
- Venetoclax–Rituximab in Relapsed or Refractory Chronic Lymphocytic LeukemiaNew England Journal of Medicine, 2018
- Venetoclax and obinutuzumab in chronic lymphocytic leukemiaBlood, 2017
- Phase I First-in-Human Study of Venetoclax in Patients With Relapsed or Refractory Non-Hodgkin LymphomaJournal of Clinical Oncology, 2017
- Phase 1b Results of a Phase 1b/2 Study of Obinutuzmab, Ibrutinib, and Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia (CLL)Blood, 2016
- Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 studyThe Lancet Oncology, 2016
- Pharmacological and Protein Profiling Suggests Venetoclax (ABT-199) as Optimal Partner with Ibrutinib in Chronic Lymphocytic LeukemiaClinical Cancer Research, 2015